Clinical Trials Logo

Neoplastic Cells, Circulating clinical trials

View clinical trials related to Neoplastic Cells, Circulating.

Filter by:

NCT ID: NCT03928210 Completed - Breast Cancer Clinical Trials

Digoxin Induced Dissolution of CTC Clusters

Start date: July 8, 2020
Phase: Early Phase 1
Study type: Interventional

This single arm therapeutic exploratory study of digoxin in patients with advanced or metastatic breast cancer investigates whether cardiac glycosides are able to disrupt CTC clusters in breast cancer patients.

NCT ID: NCT03732339 Completed - Clinical trials for Locally Advanced Breast Cancer

CTC in Predicting Neoadjuvant Chemotherapy Among LABC Patients: a Single-center, Prospective, Exploratory Clinical Trial

CTCNeoBC
Start date: August 24, 2018
Phase: N/A
Study type: Interventional

The GILUPI CellCollector® is the first in vivo CTC isolation product worldwide, which is CE approved. The purpose of this clinical trial is to evaluate the predictive value of CTC in neoadjuvant chemotherapy among locally advanced breast cancer patients.

NCT ID: NCT03700541 Completed - Colorectal Cancer Clinical Trials

Influence of Opioid Analgesia on Circulating Tumor Cells in Laparoscopic Colorectal Cancer Surgery

POACC-2
Start date: January 7, 2019
Phase: Phase 4
Study type: Interventional

To compare the effects of three types of perioperative analgesia on the number of circulating tumor cells following radical colorectal cancer surgery. To find correlations with other perioperative factors and clinical/pathological disease characteristics.

NCT ID: NCT03700411 Completed - Colorectal Cancer Clinical Trials

Influence of Opioid Analgesia on Circulating Tumor Cells in Open Colorectal Cancer Surgery

POACC-1
Start date: January 7, 2019
Phase: Phase 4
Study type: Interventional

To compare the effects of three types of perioperative analgesia on the number of circulating tumor cells following radical colorectal cancer surgery. To find correlations with other perioperative factors and clinical/pathological disease characteristics.

NCT ID: NCT03479099 Completed - Clinical trials for Circulating Tumor Cell

Liquid Biopsy in Lung Cancer

Start date: March 12, 2018
Phase:
Study type: Observational

The purpose of this study is to assess clinical utility of combined circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) in the diagnosis of primary lung cancer.

NCT ID: NCT03340844 Completed - Metastasis Clinical Trials

Role of CTC´s Spread During Pancreaticoduodenectomy in Patients With Pancreatic and Periampullary Tumors

CETUPANC
Start date: December 15, 2017
Phase: N/A
Study type: Interventional

This multicentre, prospective and randomized study aims(1:1) to compare the rate of recurrence, metastasis and survival according to the levels of intraoperative circulating tumor cells (CTCs) during cephalic duodenopancreatectomy in patients with pancreatic and periampullary tumors.

NCT ID: NCT03337347 Completed - Colorectal Cancer Clinical Trials

Clinical Significance of Detecting CEA and CK20 mRNA-positive Cells in Colorectal Cancer Patients

Start date: January 1, 2004
Phase: N/A
Study type: Interventional

To determine whether the presence of circulating/disseminated tumor cells (CTCs/DTCs) in the blood and bone marrow of colorectal cancer (CRC) patients with localized disease is a negative prognostic factor, and to find correlations with other clinical/pathological disease characteristics.

NCT ID: NCT03162198 Completed - Clinical trials for Hepatocellular Carcinoma

Frequency of Circulating Tumor Cells (CTCs) and Amount of Cell-free DNA (cfDNA) in Cirrhotic Patients With Hepatocellular Carcinoma (HCC)

Start date: May 15, 2017
Phase:
Study type: Observational

All consecutive patients with liver cirrhosis, with clinical and imaging features suggestive of Hepatocellular Carcinoma (HCC) attending the Department of Hepatology, Institute of Liver and Biliary Sciences (ILBS) from February 2017 to December 2018 will be evaluated for inclusion.Based on the previous years data of HCC patients admitted to ILBS. Cirrhotic patients aged 18-70 years, with HCC proven by typical radiological features of arterial enhancement and delayed wash-out, on one or both of dynamic Computerized Tomographic or dynamic Magnetic Resonance Imaging (MRI), as per updated American Association for the Study of Liver Disease (AASLD) guidelines (details in appendix1). Age and gender matched patients with cirrhosis, but without HCC, seen during the same study period will serve as controls. Patient characteristics, etiology of cirrhosis, and liver function parameters will be noted. Investigator will stage the included patients as per the Barcelona Cancer of Liver Cancer (BCLC) criteria (details in appendix1). Investigator will then estimate Circulating Tumor Cells (CTC) and cfDNA in peripheral blood samples of the patients and controls.

NCT ID: NCT03161821 Completed - Solid Tumor, Adult Clinical Trials

Circulating Tumor Cells in Solid Tumors

Start date: December 9, 2011
Phase:
Study type: Observational

The purpose of this study is to identify circulating tumor cells in patients with solid tumors. Quantify and characterize these cells, collect patient information in regards to the patient's cancer. Develop a database and a sample repository where future analysis could be done.

NCT ID: NCT03101046 Completed - Chemotherapy Clinical Trials

Treatment of Metastatic Castrate Resistant Prostate Cancer Patients According to Circulating Tumor Cells Kinetic

TACTIK
Start date: November 15, 2018
Phase: Phase 2
Study type: Interventional

This study compares the biological activity of cabazitaxel (6 cycles) to that of docetaxel (6 cycles) in metastatic castrate-resistant prostate cancer (mCRPC) patients with docetaxel resistant mCRPC defined as ≥5 circulating tumor cells (CTCs) / 7.5 mL after 2 cycles of docetaxel. Patients with docetaxel resistant metastatic castration-resistant prostate cancer (mCRPC) based on circulating tumor cell (CTC) enumeration (patients with ≥5 CTCs / 7.5 mL before docetaxel chemotherapy and after 2 cycles of docetaxel) will receive either 6 additional cycles of docetaxel or 6 additional cycles of cabazitaxel after randomisation. A cohort of patients with docetaxel sensitive metastatic castration-resistant prostate cancer (mCRPC) based on circulating tumor cell (CTC) enumeration (patients ≥5 CTCs / 7.5 mL before docetaxel chemotherapy and <5 CTCs / 7.5 mL after 2 cycles of docetaxel) will receive 6 additional cycles of docetaxel.